BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2715 related articles for article (PubMed ID: 7894087)

  • 1. Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
    Kamishohara M; Kawai H; Sakai T; Isoe T; Hasegawa K; Mochizuki J; Uchida T; Kataoka S; Yamaki H; Tsuruo T
    Oncol Res; 1994; 6(8):383-90. PubMed ID: 7894087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
    Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
    Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
    Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subrenal capsule assay using nude mice].
    Kikuchi H; Asamura M; Gamoh M; Ohuchi H; Wakui A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):532-41. PubMed ID: 2321981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
    Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of immuno-drug conjugates on growth of human gastric cancer xenograft in subrenal capsule of nude mice].
    Zhang SY; Li S; Chen LJ; Shu YH; Zhang XY; Chen XT
    Zhongguo Yao Li Xue Bao; 1990 Nov; 11(6):556-60. PubMed ID: 2130622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
    Burger AM; Kaur G; Hollingshead M; Fischer RT; Nagashima K; Malspeis L; Duncan KL; Sausville EA
    Clin Cancer Res; 1997 Mar; 3(3):455-63. PubMed ID: 9815705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
    Kamishohara M; Kawai H; Sakai T; Uchida T; Tsuruo T; Otake N
    Cancer Chemother Pharmacol; 1996; 38(6):495-8. PubMed ID: 8823489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
    Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
    Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
    Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
    J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spicamycin derivative].
    Mizumura Y
    Nihon Rinsho; 2006 Feb; 64(2):322-8. PubMed ID: 16454188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 136.